Commencement of Patient Recruitment

AI SummaryClose X

CRISM Therapeutics Corporation has announced a significant milestone with the formal activation of the first clinical site for its Phase II study of irinotecan ChemoSeed® for glioblastoma, and patient recruitment has now commenced. This marks the transition of the study into its active clinical phase, with the company's immediate focus on screening and assessing eligible participants. The next key development will be the successful treatment of the first patient, after which a further update will be provided.

Disclaimer*

UK 100

Latest directors dealings